New Elite Feature: Chart Magnifying Glass

MapLight Therapeutics, Inc.

Contributing Author

Recent Articles by MapLight Therapeutics, Inc.

Jun-22	MapLight Announces Topline Results from Phase 2 IRIS Study for ML-004 in Autism Spectrum Disorder MPLT GlobeNewswire
May-14	MapLight Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update MPLT GlobeNewswire
May-08	MapLight Therapeutics to Participate in Upcoming Investor Conferences MPLT -6.16% GlobeNewswire
May-01	MapLight Therapeutics Announces Completion of Enrollment in ZEPHYR Phase 2 Trial and Updates Expected Timing of Topline Results MPLT GlobeNewswire
Mar-26	MapLight Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update MPLT +6.01% GlobeNewswire
Mar-02	MapLight Therapeutics to Participate in Upcoming Investor Conferences MPLT GlobeNewswire
Jan-09	MapLight Therapeutics Updates Expected Timing of Topline Results for Ongoing Phase 2 Studies to Q3 2026 MPLT GlobeNewswire
Jan-05	MapLight Therapeutics Receives Fast Track Designation for ML-007C-MA for Alzheimer's Disease Psychosis MPLT GlobeNewswire
Dec-16	SandboxAQ and MapLight Therapeutics Announce Strategic Collaboration to Discover and Develop Novel CNS Therapies MPLT GlobeNewswire
Dec-04	MapLight Therapeutics Reports Third Quarter Financial Results and Highlights Corporate Progress MPLT +8.39% GlobeNewswire
Oct-29	MapLight Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares MPLT GlobeNewswire
Oct-26	MapLight Therapeutics Announces Pricing of Initial Public Offering MPLT GlobeNewswire

Affiliate • Advertise • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information

Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2026 Finviz.com. All Rights Reserved. Export All Screener Data (CSV)